Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'
Ann Rheum Dis
.
2023 May;82(5):e119.
doi: 10.1136/annrheumdis-2021-220047.
Epub 2021 Feb 22.
Authors
Piero Ruscitti
1
,
Giorgio Sesti
2
,
Paola Cipriani
3
,
Roberto Gerli
4
,
Roberto Giacomelli
5
Affiliations
1
Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy piero.ruscitti@univaq.it.
2
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Roma, Lazio, Italy.
3
Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
4
Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
5
Unit of Allergology, Immunology, Rheumatology, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
PMID:
33619161
DOI:
10.1136/annrheumdis-2021-220047
No abstract available
Keywords:
arthritis; biological therapy; interleukin 1 receptor antagonist protein; rheumatoid.
Publication types
Letter
Comment
MeSH terms
Arthritis, Rheumatoid* / epidemiology
Chemokines
Cytokines
Diabetes Mellitus*
Humans
Substances
Cytokines
Chemokines